Section Arrow
Quote
ARQT.NASDAQ
- Arcutis Biotherapeutics
Quotes are at least 15-min delayed:2026/04/09 08:47 EDT
Pre Market
Last
 24.34
-0.27 (-1.10%)
Bid
23.36
Ask
24.58
High 24.38 
Low 24.33 
Volume 19 
Regular Hours (Closed)
Last
 24.61
+1.34 (+5.76%)
Day High 
24.7 
Prev. Close
23.27 
1-M High
25.53 
Volume 
1.17M 
Bid
23.36
Ask
24.58
Day Low
23.65 
Open
24.28 
1-M Low
21.12 
Market Cap 
2.89B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 22.77 
20-SMA 22.85 
50-SMA 24.76 
52-W High 31.77 
52-W Low 12.42 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.13/0.83
Enterprise Value
3.00B
Balance Sheet
Book Value Per Share
1.53
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
376.07M
Operating Revenue Per Share
0.40
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ZYMEZymeworks-------- 
Pre Market 26.41 -0.3 -1.12%
ZVRAZevra Therapeutics-------- 
Pre Market 9.59 0 0.00%
ZURAZura Bio Limited-------- 
Pre Market 5.73 +0.03 +0.53%
ZNTLZentalis Pharmaceuticals-------- 
Pre Market 3.04 +0.28 +10.14%
ZLABZai Lab Limited-------- 
Pre Market 21.1744 -0.2156 -1.01%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.